Skip to main navigation
Skip to search
Skip to main content
Sort by
Immunology and Microbiology
Myeloid
100%
Tyrosine
100%
Insulin
100%
Glucose
100%
Kinase
100%
Phosphotransferase
100%
Insulin Response
36%
Skeletal Muscle
27%
Glucose Transport
18%
Insulin Sensitivity
18%
Cardiovascular System
18%
Body Weight
9%
Insulin Release
9%
Glycogen Muscle Level
9%
Positron Emission Tomography
9%
Muscle
9%
Glycogen
9%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
100%
Insulin
100%
Glucose
100%
Chronic Myelogenous Leukemia
100%
Insulin Response
36%
Glucose Intake
27%
Skeletal Muscle
27%
Cardiovascular Disease
18%
Insulin Sensitivity
18%
Hyperglycemia
18%
Glycogen
18%
Glucose Uptake
18%
Fluorodeoxyglucose F 18
18%
Body Weight
9%
Diabetes Mellitus
9%
Positron Emission Tomography
9%
Glycemic
9%
Insulin Release
9%
Glucose Infusion
9%
Infusion Rate
9%
Glucose Tolerance
9%
Pathogenesis
9%
Biochemistry, Genetics and Molecular Biology
Tyrosine Kinase Inhibitor
100%
Myeloid
100%
Insulin
100%
Glucose
100%
Nilotinib
81%
Insulin Response
36%
Skeletal Muscle
27%
Imatinib
27%
Glucose Transport
18%
Insulin Sensitivity
18%
Hyperglycemia
18%
Insulin Release
9%
Body Weight
9%
Positron Emission Tomography
9%
Glycogen Muscle Level
9%
Glycogen
9%
Glycemia
9%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Chronic Myeloid Leukemia
100%
Insulin
100%
Glucose
100%
Nilotinib
69%
Imatinib
23%
Hyperglycemia
15%
Fluorodeoxyglucose F 18
15%
Cardiovascular Disease
15%
Glycogen
15%
Diabetes Mellitus
7%
Polyethylene Terephthalate
7%
Pathogenesis
7%